智通财经APP讯,北海康成-B(01228)公布,用于治疗戈谢病(GD)的CAN103(维拉苷酶β)已获得国家药监局药品审批中心优先审评资格。
CAN103(维拉苷酶β)获得优先审评资格是对中国GD患者迫切的医疗需求及公司临床试验结果优势的认可。公司正在全力以赴加速CAN103(维拉苷酶β)的审批流程,使其成为首个在中国本土研发和生产的酶替代疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.